Sichuan Kelun Pharmaceutical Co., Ltd.

Overview

Sichuan Kelun Pharmaceutical Co., Ltd. is a leading pharmaceutical company based in China, focused on research, development, and manufacturing of a wide range of pharmaceutical products. The company is known for its emphasis on innovation in the development of novel therapeutics, particularly in the fields of oncology and anti-infectives.

Therapeutic areas

API / Drug Master Files

Sichuan Kelun Pharmaceutical Co., Ltd. holds 19 active (19 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• SUCROFERRIC OXYHYDROXIDEActive2026-03-11
• NETUPITANTActive2025-12-29
• NERATINIB MALEATEActive2025-12-15
• APREPITANTActive2025-12-15
• ZINC ACETATEActive2025-11-19
• REGORAFENIBActive2025-10-27
• IBRUTINIBActive2025-09-28
• FINERENONEActive2025-07-31
• PEMAFIBRATEActive2025-06-17
• APALUTAMIDEActive2025-05-29
• SIPONIMODActive2025-05-22
• POSACONAZOLEActive2025-04-17
• OMADACYCLINE TOSYLATEActive2025-03-26
• SACUBITRIL VALSARTAN SODIUMActive2025-02-27
• ENZALUTAMIDEActive2024-12-19

Showing 15 of 19 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Sichuan Kelun Pharmaceutical Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.